New Medication Release of Semglee

Semglee (insulin glargine-yfgn) co-developed by Viatris and Biocon Biologics, is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes. Approval of these insulin products can provide patients with additional safe, high-quality and potentially cost-effective options for treating diabetes. Semglee is U.S. Food and Drug Administration approved and indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.

Semglee is a once daily long-acting insulin analog (100 units/ml) and is both biosimilar to, and interchangeable with its reference product Lantus (insulin glargine). Semglee offers similar clinical benefits compared with Lantus including duration of action, rate of hypoglycemia and effect on changes HbA1c and fasting plasma glucose from baseline when used as instructed.

Semglee (insulin glargine-yfgn) is offered in 10 mL vials and 3 mL prefilled pens. Dosing of Semglee (insulin glargine-yfgn), like Lantus, should be individualized based on the patient’s needs.

Current availability of Semglee may be limited for some wholesalers.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.